Verdad Advisers’s ADMA Biologics ADMA Stock Holding History

Verdad Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-49,018	Closed	-$548K	–	94
2024 Q2	$548K	Buy	+49,018	New	+$411K	0.63%	65

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Verdad Advisers's ADMA Position: Q3 2024 in Review

Verdad Advisers sold out of ADMA Biologics (ADMA) in Q3 2024, closing a stake of 49,018 shares — an estimated $548K sold.

Verdad Advisers first reported a position in ADMA in Q2 2024 and held it in 1 quarter. The position peaked at $548K in Q2 2024. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

Verdad Advisers reported no remaining ADMA Biologics position as of Q3 2024 after selling out during the quarter.
Verdad Advisers sold 49,018 ADMA Biologics shares in Q3 2024, an estimated $548K.
Verdad Advisers first reported a position in ADMA Biologics in Q2 2024 and held it in 1 quarter.
Verdad Advisers's ADMA Biologics position peaked at $548K in Q2 2024.
306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Verdad Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.